Q32 Bio (QTTB) Net Cash Flow Growth (5y) (2022 - 2026)
Q32 Bio (QTTB) Net Cash Flow Growth (5y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Q32 Bio | 214.11 Mn | 163.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.12% |
| Dec 31, 2025 | -15.09% |
| Sep 30, 2025 | -20.67% |
| Jun 30, 2025 | -19.52% |
| Mar 31, 2025 | -16.43% |
| Dec 31, 2024 | 14.12% |
| Sep 30, 2024 | 25.74% |
| Jun 30, 2024 | -17.49% |
| Mar 31, 2024 | 109.15% |
| Dec 31, 2023 | -47.22% |
| Sep 30, 2023 | 17.87% |
| Jun 30, 2023 | -17.43% |
| Mar 31, 2023 | -18.42% |
| Dec 31, 2022 | 27.62% |
| Sep 30, 2022 | -30.05% |
| Jun 30, 2022 | -64.10% |
| Mar 31, 2022 | 55.66% |